MedTrace Logo

The Effectiveness of a Mobile Game Intervention in Alcohol Use Disorder

NCT07103785 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-08-05

No results posted yet for this study

Summary

The aim of this study was to evaluate the effectiveness of a mobile game application targeting attentional bias modification for alcohol stimuli in patients with Alcohol Use Disorder. Attentional bias is the tendency for individuals to pay more attention to some environmental stimuli than others. Previous evidence suggests that attentional bias for alcohol stimuli is associated with severity of drinking and craving. The research questions are as follows;

* Does the developed mobile game application reduce the attentional bias related to alcohol?
* Does the developed mobile game application reduce alcohol craving severity?
* Does the developed mobile game application reduce the severity of alcohol drinking? The researchers will evaluate the effectiveness of the mobile game, which aims to reduce attentional bias to alcohol stimuli, as standard treatment for Alcohol Use Disorder (medical treatment) versus standard treatment + mobile game application group.

Participants,

* Comply with the medical treatment prescribed by the doctor
* Use the mobile gaming app every other day for one month
* Come back in a month for an evaluation
* Be available for a telephone interview three months after the first interview

Conditions

Interventions

OTHER

Mobile game app

The mobile game designed to modify attentional bias toward alcohol-related cues was developed by integrating game elements into a modified version of the dot-probe task. This gamified intervention was installed on the smartphones of participants assigned to the experimental group, and each participant was provided with a unique username and password for access. Participants were instructed to engage with the mobile game every other day over one month.

DRUG

Akamprosat or Naltrekson or combined medical treatment (Akamprosat and Naltrekson)

Medicines prescribed by a doctor for the treatment of Alcohol Use Disorder (Akamprosat or Naltrekson or combined medical treatment (Akamprosat and Naltrekson))

Sponsors & Collaborators

  • TC Erciyes University

    collaborator OTHER

  • University of Yalova

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-11
Primary Completion
2025-05-30
Completion
2025-06-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07103785 on ClinicalTrials.gov